Regeneron Pharmaceuticals (REGN) Asset Utilization Ratio (2010 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Asset Utilization Ratio of 0.38 for Q2 2026, little changed year-over-year from 0.38 in Q2 2025, and up 2.65% quarter-over-quarter from 0.37 in Q1 2026.
Regeneron Pharmaceuticals (REGN) Asset Utilization Ratio (2010 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Asset Utilization Ratio history runs 17 years deep, the most recent figure standing at 0.38 for Q2 2026.
- In Q2 2026, Asset Utilization Ratio changed 0.25% year-over-year to 0.38; the TTM figure through Jun 2026 stood at 0.38 (changed 0.25% YoY), while the FY2025 annual figure was 0.37, down 8.65% from the prior year.
- Asset Utilization Ratio for Q2 2026 stood at 0.38, up from 0.37 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.52 in Q1 2022, with the low at 0.21 in Q4 2022.
- The 5-year median for Asset Utilization Ratio is 0.38 (2025), against an average of 0.37.
- The sharpest annual moves came in 2022 and 2023: Asset Utilization Ratio sank 68.08% in 2022, then jumped 92.45% in 2023.
- Regeneron Pharmaceuticals' Asset Utilization Ratio stood at 0.21 in 2022, then surged by 92.45% to 0.4 in 2023, then fell by 6.07% to 0.38 in 2024, then decreased by 5.92% to 0.36 in 2025, then rose by 5.86% to 0.38 in 2026.
- Business Quant data shows REGN's Asset Utilization Ratio at 0.38 in Q2 2026, 0.37 in Q1 2026, and 0.36 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.69 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 186.67 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.13 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 0.90 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 0.54 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 0.38 |
| Mar 31, 2026 | 0.37 |
| Dec 31, 2025 | 0.36 |
| Sep 30, 2025 | 0.36 |
| Jun 30, 2025 | 0.38 |
| Mar 31, 2025 | 0.37 |
| Dec 31, 2024 | 0.38 |
| Sep 30, 2024 | 0.38 |
| Jun 30, 2024 | 0.38 |
| Mar 31, 2024 | 0.39 |
| Dec 31, 2023 | 0.40 |
| Sep 30, 2023 | 0.31 |
| Jun 30, 2023 | 0.31 |
| Mar 31, 2023 | 0.31 |
| Dec 31, 2022 | 0.21 |
| Sep 30, 2022 | 0.39 |
| Jun 30, 2022 | 0.42 |
| Mar 31, 2022 | 0.52 |
| Dec 31, 2021 | 0.65 |
| Sep 30, 2021 | 0.60 |